This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 May 1;25(13):1637-8.

doi: 10.1200/JCO.2006.09.8376.

Integrin inhibitors reaching the clinic

Roger Stupp, Curzio Ruegg

PMID: 17470853
DOI: 10.1200/JCO.2006.09.8376

Editorial

Integrin inhibitors reaching the clinic

Roger Stupp et al. J Clin Oncol. 2007.

. 2007 May 1;25(13):1637-8.

doi: 10.1200/JCO.2006.09.8376.

Authors

Roger Stupp, Curzio Ruegg

PMID: 17470853
DOI: 10.1200/JCO.2006.09.8376

No abstract available

PubMed Disclaimer

Comment on

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. Nabors LB, et al. J Clin Oncol. 2007 May 1;25(13):1651-7. doi: 10.1200/JCO.2006.06.6514. J Clin Oncol. 2007. PMID: 17470857 Free PMC article. Clinical Trial.

Similar articles

Integrins as target: first phase III trial launches, but questions remain.
Carter A. Carter A. J Natl Cancer Inst. 2010 May 19;102(10):675-7. doi: 10.1093/jnci/djq186. Epub 2010 May 11. J Natl Cancer Inst. 2010. PMID: 20460633 No abstract available.
Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
Colevas AD, Scharf O, Schoenfeldt M. Colevas AD, et al. Oncology (Williston Park). 2004 Dec;18(14):1778, 1781-2, 1784. Oncology (Williston Park). 2004. PMID: 15700626 No abstract available.
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Reardon DA, et al. Future Oncol. 2011 Mar;7(3):339-54. doi: 10.2217/fon.11.8. Future Oncol. 2011. PMID: 21417900
"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Markman M. Markman M. Arch Intern Med. 2006 Jul 24;166(14):1446-8. doi: 10.1001/archinte.166.14.1446. Arch Intern Med. 2006. PMID: 16864753 Review. No abstract available.
Alpha v integrin inhibitors and cancer therapy.
Tucker GC. Tucker GC. Curr Opin Investig Drugs. 2003 Jun;4(6):722-31. Curr Opin Investig Drugs. 2003. PMID: 12901232 Review.

See all similar articles

Cited by

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Choi HJ, et al. Cancer Metastasis Rev. 2015 Mar;34(1):19-40. doi: 10.1007/s10555-014-9538-9. Cancer Metastasis Rev. 2015. PMID: 25544368 Free PMC article. Review.
Biologic Mechanisms Linked to Prognosis in Ovarian Cancer that May Be Affected by Aging.
Chon HS, Sehovic M, Marchion D, Walko C, Xiong Y, Extermann M. Chon HS, et al. J Cancer. 2019 Jun 2;10(12):2604-2618. doi: 10.7150/jca.29611. eCollection 2019. J Cancer. 2019. PMID: 31258768 Free PMC article. Review.
Integrins as Key Mediators of Metastasis.
Cáceres-Calle D, Torre-Cea I, Marcos-Zazo L, Carrera-Aguado I, Guerra-Paes E, Berlana-Galán P, Muñoz-Félix JM, Sánchez-Juanes F. Cáceres-Calle D, et al. Int J Mol Sci. 2025 Jan 22;26(3):904. doi: 10.3390/ijms26030904. Int J Mol Sci. 2025. PMID: 39940673 Free PMC article. Review.
Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.
D'Amico G, Robinson SD, Germain M, Reynolds LE, Thomas GJ, Elia G, Saunders G, Fruttiger M, Tybulewicz V, Mavria G, Hodivala-Dilke KM. D'Amico G, et al. PLoS One. 2010 Mar 22;5(3):e9766. doi: 10.1371/journal.pone.0009766. PLoS One. 2010. PMID: 20339539 Free PMC article.
Integrin inhibitors as a therapeutic agent for ovarian cancer.
Sawada K, Ohyagi-Hara C, Kimura T, Morishige K. Sawada K, et al. J Oncol. 2012;2012:915140. doi: 10.1155/2012/915140. Epub 2011 Dec 25. J Oncol. 2012. PMID: 22235205 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database